GNMX Aevi Genomic Medicine, Inc.

1.18
-0.02  -2%
Previous Close 1.20
Open 1.18
Price To book 1.78
Market Cap 43.79M
Shares 37,110,000
Volume 202,822
Short Ratio 2.01
Av. Daily Volume 869,894

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17859878
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828533
  3. 8-K - Current report 17828517
  4. DEF 14A - Other definitive proxy statements 17800640
  5. 8-K - Current report 17779842

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017 with data due mid-2018.
AEVI-001 (NFC-1)
ADHD - 9-Gene subset
Phase 1/2 data due 2H 2017.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD

Latest News

  1. Blog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results
  2. Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results
  3. Investor Network: Aevi Genomic Medicine, Inc. to Host Earnings Call
  4. Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates
  5. Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference
  6. GNMX: New SAGA Data May Be Just What The Doctor Ordered
  7. Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  8. Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
  9. Aevi Genomic Medicine to Present at the 16th Annual Needham Healthcare Conference
  10. GNMX: SAGA Misses Primary Endpoint But Data Warrants Optimism
  11. Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi Genomic Medicine
  12. Why Aevi Genomic Medicine Got Crushed Today
  13. Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
  14. Aevi Genomic Medicine to Present at the Oppenheimer 27th Annual Healthcare Conference
  15. Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  16. Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference
  17. Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia
  18. Aevi Genomic Medicine Announces 2017 Investor Day
  19. Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference

SEC Filings

  1. CT ORDER - Confidential treatment order 17859878
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17828533
  3. 8-K - Current report 17828517
  4. DEF 14A - Other definitive proxy statements 17800640
  5. 8-K - Current report 17779842
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 17724125
  7. 8-K - Current report 17700390
  8. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17676823
  9. 8-K - Current report 17676811
  10. 8-K - Current report 17640312